Get the Stockscreener App
9.18
7.12%
0.61
Pre-market:
8.99
-0.19
-2.07%
Hcw Biologics Inc stock is traded at $9.18, with a volume of 224.01K.
It is up +7.12% in the last 24 hours and up +30.21% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
See More
Previous Close:
$8.57
Open:
$8.36
24h Volume:
224.01K
Relative Volume:
0.37
Market Cap:
$13.22M
Revenue:
$3.50M
Net Income/Loss:
$-37.33M
P/E Ratio:
-9.18
EPS:
-1
Net Cash Flow:
$-19.15M
1W Performance:
-8.66%
1M Performance:
+30.21%
6M Performance:
-75.77%
1Y Performance:
-79.32%
1-Day Range:
$8.30
$9.33
1-Week Range:
$8.03
$11.22
52-Week Range:
$5.0001
$100.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
9.18 | 16.05M | 3.50M | -37.33M | -19.15M | -1.00 |
|
ONC
Beigene Ltd Adr
|
236.86 | 24.29B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.18 | 110.94B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2996 | 45.05M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
614.79 | 61.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.73 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Hcw Biologics Inc Stock (HCWB) Latest News
Insider Buying: Hing Wong Acquires Additional Shares of HCW Biol - GuruFocus
HCW Biologics Enters Securities Purchase Agreement - TipRanks
HCW Biologics (NASDAQ:HCWB) Trading 9.1% Higher – Still a Buy? - Defense World
HCW Biologics Inc Reports Q1 2025 Earnings: Revenue at $5,065, Net Loss Reduced to $2.2 Million - GuruFocus
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - GlobeNewswire
HCW Biologics Closes $5 Million Public Offering - TipRanks
HCW Biologics (HCWB) Launches $5M Follow-On Offering - GuruFocus
HCW Biologics Raises Fresh Capital: $5M Follow-On Offering Includes Attractive Warrant Package - Stock Titan
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offer - GuruFocus
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offering | HCWB Stock News - GuruFocus
Three layers of uncertainty - The Globe and Mail
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - Yahoo Finance
Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales - Benzinga
Trading Halt for HCW Biologics (HCWB) Due to Volatility | HCWB S - GuruFocus
Trading Resumes for HCW Biologics (HCWB) | HCWB Stock News - GuruFocus
HCW Biologics Reports Positive Results For HCW9206 And Opens Commercial Partnership Talks - Nasdaq
HCW Biologics Says Studies Show HCW9206 Fusion Protein Addresses Key Challenges for CAR-T Therapies; Shares Surge - marketscreener.com
HCW Biologics (HCWB) Unveils Innovative Pathway for Enhanced CAR - GuruFocus
HCW Biologics presents novel CAR-T cell enhancer By Investing.com - Investing.com Nigeria
HCW Biologics presents novel CAR-T cell enhancer - Investing.com
HCW Biologics Announces Positive Results of Studies of - GlobeNewswire
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization - TradingView
Friday’s Insider Moves: Top Buys and Sells in US Stocks Revealed By Investing.com - Investing.com South Africa
Friday’s Insider Moves: Top Buys and Sells in US Stocks Revealed - Investing.com
Prediction: Warren Buffett May Be Shifting Out of His Berkshire Hathaway CEO Role, but He's Not Done Investing - The Globe and Mail
Should You Buy Rivian Stock While It Is Still Below $15? - The Globe and Mail
This Well-Known Toy Company Is Set to Be an Outperformer if the Tariff War Continues - The Globe and Mail
Insider Buying: Gary Winer Acquires Shares of HCW Biologics Inc (HCWB) - GuruFocus
Hcw biologics CEO acquires $2.41 million in stock By Investing.com - Investing.com Nigeria
HCW Biologics Executives and Directors Make Significant Stock Purchases - TradingView
Hcw biologics CEO acquires $2.41 million in stock - Investing.com Australia
HCW Biologics Executives Increase Stake in Company - TradingView
Tariffs, Trump, and Turmoil: ETFs to Escape U.S. Uncertainty - The Globe and Mail
Why Airline Stocks Are Flying Higher Today - The Globe and Mail
With Paychex Near Its 52-Week High, Should Investors Buy It Right Now? - The Globe and Mail
iA Financial Corporation Inc. Announces the Payment of a Dividend on Its Common Shares - The Globe and Mail
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules - ADVFN
Is XPeng’s Stock (XPEV) a Better Buy Than Tesla Stock (TSLA)? - The Globe and Mail
As the Market Fluctuates in Response to President Donald Trump's Tariffs, What Stocks Are Safe? - The Globe and Mail
Earnings To Watch: Insperity (NSP) Reports Q1 Results Tomorrow - The Globe and Mail
HCWB stock touches 52-week low at $6.99 amid sharp annual decline - Investing.com Australia
Nasdaq 100 Index Today: QQQ Stock Rallies on Recent Earnings Beats - The Globe and Mail
HCW Biologics (NASDAQ:HCWB) Trading 0.1% Higher – Here’s Why - Defense World
HCW Biologics faces lawsuit over construction contract breach - Investing.com Australia
HCW Biologics faces lawsuit over construction contract breach By Investing.com - Investing.com Canada
This SpaceX Rival Is Soaring on a New Multibillion-Dollar Opportunity. Should You Buy the Stock Now? - The Globe and Mail
HCW Biologics enters key agreements; SEC non-review of filing By Investing.com - Investing.com South Africa
HCW Biologics enters key agreements; SEC non-review of filing - Investing.com
HCWB stock touches 52-week low at $8.04 amid market challenges By Investing.com - Investing.com South Africa
HCWB stock touches 52-week low at $8.04 amid market challenges - Investing.com Canada
Earnings To Watch: Applied Digital (APLD) Reports Q1 Results Tomorrow - The Globe and Mail
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):